700 Saginaw Drive
Redwood City, CA 94063
United States
650 481 6801
https://www.revmed.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 411
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Mark A. Goldsmith Ph.D. | CEO, President & Chairman | 1,12M | 2,85M | 1962 |
Mr. Jack Anders | Chief Financial Officer | 665,28k | 1,02M | 1977 |
Ms. Margaret A. Horn J.D. | Chief Operating Officer | 811,08k | 1,68M | 1963 |
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development | 812,17k | S.O. | 1961 |
Ms. Xiaolin Wang | Executive Vice President of Development | 633,74k | S.O. | 1971 |
Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | S.O. | S.O. | S.O. |
Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | S.O. | S.O. | 1981 |
Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | S.O. | S.O. | S.O. |
Mr. Walter Reiher Ph.D. | Chief Information Officer | S.O. | S.O. | S.O. |
Ms. Jan Smith Ph.D. | Chief Scientific Officer | S.O. | S.O. | S.O. |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
L’ISS Governance QualityScore de Revolution Medicines, Inc. en date du 1 juin 2024 est 7. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 8; Compensation : 9.